Gregory Ferenstein
Gregory Ferenstein is a senior fellow in drug policy at Reason Foundation.
-
Exploring new data on the safety of psychedelics
Reason Foundation’s recently published psychedelics dashboard offers a clearer picture of how psilocybin access is affecting communities.
-
Legislative approaches that could improve access to psychedelic-based medicine
Psychedelics-assisted therapy represents a promising treatment for many mental health issues.
-
Psychedelics Policy Newsletter: States propose legalization, optimism for Trump administration nominee, and more
Plus: A policy brief on psychedelics and neurodegenerative treatments, alternatives to 'double-blind' trials, and more.
-
State psychedelics legalization and policy roundup — February 2025
New York proposes a medical retail model, Colorado opens for business, and more.
-
Psychedelics Policy Newsletter: Trump administration recommendations, Massachusetts loss, and more
Plus: Government funding for addiction research, veteran’s administration pursues psychedelics, and more.
-
State psychedelics legalization and policy roundup — December 2024
Possible psychedelic reform on the horizon, a ballot initiative in Massachusetts fails, and more.
-
Psychedelic drug policy recommendations for the incoming Trump administration
The incoming Trump administration has promised sweeping reforms, and that might include reversing the federal suppression of psychedelics.
-
Psilocybin access would improve mental health care in Massachusetts
Ballot Question 4 would create a regulated framework for legal, professionally facilitated psychedelic services and therapy.
-
Psychedelics Policy Newsletter: MDMA rejection, advocating for lower state fees in Colorado, and more
Plus: A profile of ibogaine advocate Bryan Hubbard, the Drug Enforcement Administration head worries about ketamine, and more.
-
State psychedelics legalization and policy roundup — September 2024
A Massachusetts ballot initiative moves forward, Colorado considers high business application and renewal fees, and more.
-
Colorado should rethink proposed psychedelic application fees
There are several areas where the draft permanent rules on fees for psychedelic applications proposed by the Colorado Department of Revenue could be enhanced.
-
Psychedelics Policy Newsletter: A glimpse into Colorado after psychedelics legalization, a gathering of conservative legislators, and more
Plus: Food and Drug Administration approval of MDMA is tentative, the psychedelic origins of Whole Foods, and more.
-
State psychedelics legalization and policy roundup — July 2024
Psychedelics on the ballot in Massachusetts, Colorado proposes new regulatory rules, and Arizona Gov. Hobbs vetoes a psychedelics bill.
-
Colorado could improve regulatory rules regarding psychedelic use
As Colorado establishes an operating regulatory framework for The Natural Medicine Health Act, there is room for improvement in rulemaking.
-
A glimpse into Colorado’s emerging legal pyschedelics scene
Colorado became the first state in America where residents can legally grow and share psilocybin mushrooms in 2022.
-
How the FDA can safely approve a promising but controversial mental health drug
The FDA’s existing processes may be able to address the advisory committee’s worries about the previous tests.
-
States can legalize MDMA for pharmaceutical use even if the federal government does not
States have many options when considering the legalization or decriminalization of psychedelic medicines within their borders.
-
New Jersey Senate Bill 2283 would decriminalize psilocybin
Senate Bill 2283 would allow personal possession and cultivation of psilocybin in a private residence.
